Wellesley, Mass., June 20, 2017 (GLOBE NEWSWIRE) —
Fast-moving developments in 3D cell culture tools and technology are accelerating cancer research and clinical applications, along with other medical research and safety applications. A new report by BCC Research forecasts that some segments could see CAGR as high as 44% in products for pharmaceuticals development through 2021. In another example, neurological safety testing could grow from a $5 million segment in 2015 to $95 million by 2021, according to 3D Cell Cultures: Technologies and Global Markets.
New cell culture products and applications are proliferating even faster than a prior BCC Research report predicted in 2015. Companies such as ThermoFisher, GEHealthcare, MerckMillipore and a range of start-ups and spinouts are pursuing diverse market segments, from cosmetics and skin care to cardiac toxicology and metabolic reactions to new drugs. The new 3D technology allows for groundbreaking visibility into tissue and cancer behaviors in the body, compared with animal testing or more general, 2D in vitro technologies.
Bioreactors with microcarriers are another 3D application seeing rapid market growth. Skin and artificial skin substitutes have been in use for years. Now some of the knowledge behind those advancements are being applied to internal medicine from liver function and metabolic disease and other adjacent fields. These new applications promise not only improved medical safety in determining dosages and tailoring treatments to a patient’s condition and situation, but also breakthroughs in basic research, drug discovery and development.
- Existing 2D models are less representative of human physiology, and have contributed not only to late stage product failures due to adverse events, but also many believe to anemic pharma pipelines in general. As a result, 3D systems are gaining market share quickly.
- There are significant implications for mental health study and drug therapies where animal testing has shortcomings, for conditions such as Parkinson’s disease, Alzheimer’s disease or depression.
- Next-generation cancer therapies using these tools are estimated at $50 million annual market in 2015 and could grow to over $300 million annually in the US by 2021.
“The standards and best practices emerging in precision cancer care, and the new findings in CNS research could certainly speed up patient-centric care. Some call it personalized medicine, or precision medicine, and it really is a revolution compared with developing mass-market drugs. We are already seeing stem cells and –other tools having an impact thanks to 3D Cell Culture technology,” says Robert G. Hunter, senior healthcare editor at BCC Research.
About BCC Research
BCC Research is a publisher of market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering major industrial and technology sectors, including emerging markets. For more information, please visit bccresearch.com. Follow BCC Research on Twitter at @BCCResearch.
CONTACT: Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.